Mushroom poisoning.
OBJECTIVE
We aimed to review characteristics of mushrooms and mushroom poisoning and compare clinical picture, laboratory data, treatment modalities and prognostic factors in children with amanita intoxication and non-amanita mushroom poisoning.


METHODS
We analyzed 39 pediatric patients through 1994-2004, retrospectively from the patient files and evaluated the patients in two groups as patients with amanita intoxication and patients with non-amanita mushroom poisoning. All of the cases were admitted to the hospital in autumn. Twenty three (59%) of the patients were female and 16 (41%) were male. Mean age of the patients was 8.05 +/- 2.10 years.


RESULTS
Amanita phalloides toxin was detected in the serum in 8 patients. Eleven (28%) of the cases were strongly suggestive of amanita poisoning but alpha amanitin level could not be studied. The average time of appearance of symptoms after mushroom consumption, duration of symptoms, hospital stay, serum AST, ALT, PT and creatinine levels were significantly higher in patients with amanita poisoning (p<0.01). Conventional therapy, antidote therapy together with hemoperfusion were carried out in 16 (41%) of the patients. Four of the patients in whose blood amatoxin was detected (50%) and 3 of the patients highly suggestive of amanita poisoning (30%), totally 7 patients died of hepatic coma. The average time of admission to hospital, mean AST, ALT, creatinine and PT values at 3rd day were significantly higher in patients who died of hepatic coma. Prognosis was better in case of early admittance to hospital in patients with amanita poisoning.


CONCLUSIONS
Early diagnosis and treatment in mushroom poisoning can be life saving. Public awareness is very important in prevention of intoxication as well as encouraging early admission to hospitals.
Erguven
M
M
Department of Pediatrics, Ministry of Health, Goztepe Educational Hospital, Istanbul, Turkey.
Yilmaz
O
O
Deveci
M
M
Aksu
N
N
Dursun
F
F
Pelit
M
M
Cebeci
N
N
D000931:Antidotes / Q000008:administration & dosage; D002606:Charcoal / Q000008:administration & dosage; D016009:Chi-Square Distribution; D002648:Child; D004231:Diuresis; D005260:Female; D005751:Gastric Lavage; D006464:Hemoperfusion; D006801:Humans; D008297:Male; D009145:Mushroom Poisoning / Q000453:epidemiology* / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D014421:Turkey / Q000453:epidemiology
D000931:Antidotes; D002606:Charcoal